SCHEMBL3015263

SCHEMBL3015263

O=S(=O)(c1cccc(C(F)(F)F)c1)C1CCN(c2nc(Cc3ccc(Cl)c(F)c3)cs2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 2/20 0.43
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
AR P10275 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
RORC P51449 1/20 0.36
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
HTT P42858 1/20 0.34
POLB P06746 1/20 0.34
KDM1A O60341 1/20 0.34
GBA1 P04062 1/20 0.33
NR1I2 O75469 1/20 0.33
CACNA1B Q00975 1/20 0.33
CNR1 P21554 1/20 0.33
TRPV4 Q9HBA0 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016518 0.93 CTSS (0.43) CTSSKDM4EMAPTARADORA2A
SCHEMBL3016859 0.93 CTSS (0.44) CTSSKDM4EMAPTARADORA2A
SCHEMBL3015941 0.93 CTSS (0.45) CTSSKDM4EMAPTARADORA2A
SCHEMBL3015341 0.90 GPR6 (0.39) CTSSMAPTNPC1RAB9AUSP2
SCHEMBL3013571 0.90 RAB9A (0.38) CTSSMAPTNPC1RAB9AALDH1A1
SCHEMBL3013043 0.90 CTSS (0.45) CTSSKDM4EMAPTARADORA2A
SCHEMBL3019531 0.89 CTSS (0.46) CTSSKDM4EMAPTARADORA2A
SCHEMBL3014287 0.88 RAB9A (0.33) CTSSNPC1RAB9AFPR2PROKR1
SCHEMBL3019400 0.87 HTT (0.48) KDM4ERORCGAAHTTPOLB
SCHEMBL3003290 0.87 CTSS (0.46) CTSSKDM4EMAPTARADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885KDM4E 4398/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.